Post-Authorization Safety Study to Assess the Safety of Vimpat as add-on Therapy in Patients With Partial-onset Seizures
Status:
Completed
Trial end date:
2012-03-01
Target enrollment:
Participant gender:
Summary
SP942 is a non-interventional post-authorization safety study (PASS) to evaluate the
long-term safety and tolerability of Vimpat® (Lacosamide, LCM) as add-on treatment in
patients with Epilepsy 16 years and older with partial-onset seizures who are uncontrolled on
current therapy. Using reported adverse events, the incidence of certain cardiovascular and
psychiatric events will be evaluated.